HER2-positive Metastatic Breast Cancer
Conditions
Brief summary
A multicenter real-world study was conducted to gather clinicopathological data from patients with HER2-positive metastatic breast cancer who were treated with inetetamab between 2022 and 2023. The study aimed to estimate the progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) associated with inetetamab therapy.
Interventions
DRUGinetetamab
8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days
Sponsors
Liaoning Cancer Hospital & Institute
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. An age of at least 18 years or older 2. Pathologically diagnosed with HER2-positive recurrent or metastatic breast cancer 3. Having at least one measurable lesion as defined 4. Receiving inetetamab-based therapy in the recurrent or metastatic stage 5. Having traceable medical history records
Exclusion criteria
1. Pregnant or lactating women 2. Patients with other conditions deemed unsuitable for participating in this study by the researcher
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival(PFS) | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| objective response rate (ORR) | 12 months |
| Adverse events (AEs) | 12 months |
Countries
China
Outcome results
None listed